User:Mr. Ibrahem/Voclosporin

Mr. Ibrahem/Voclosporin
Clinical data
Trade names	Lupkynis
Other names	VCS, ISA247
AHFS/Drugs.com	Monograph
License data	US DailyMed: Voclosporin;
Routes of; administration	By mouth
Drug class	Calcineurin inhibitor
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-Ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhepta-4,6-dien-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone;
Chemical and physical data
Formula	C63H111N11O12
Molar mass	1214.646 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1N(C)[C@H](C(=O)N[C@H](C(=O)N(C)CC(=O)N(C)[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N(C)[C@H](C(=O)N(C)[C@H]1C(C)C)CC(C)C)CC(C)C)C)C)C)CC(C)C)C(C)C)CC(C)C)CC)[C@H](O)[C@H](C)C\C=C\C=C;
	InChI InChI=1S/C63H111N11O12/c1-25-27-28-29-41(15)53(76)52-57(80)66-44(26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27-28,35-48,50-53,76H,1,26,29-34H2,2-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b28-27+/t41-,42+,43-,44+,45+,46+,47+,48+,50+,51+,52+,53-/m1/s1; Key:BICRTLVBTLFLRD-PTWUADNWSA-N;

Voclosporin, sold under the brand name Lupkynis, is a medication used to treat lupus nephritis.^[1] It is used in those with severe disease together with mycophenolate mofetil (MMF) and corticosteroids.^[1]^[2] It is taken by mouth.^[1]

Common side effects include high blood pressure, kidney dysfunction, diarrhea, headache, cough, abdominal pain, hair loss, tremor, and mouth ulcers.^[1] Other side effects may include high potassium and QT prolongation.^[1] It is not typically used in people with long standing poor kidney function or significantly high blood pressure.^[1] Use in pregnancy may harm the baby.^[1] It interacts with grapefruit.^[1] It is a calcineurin inhibitor.^[1]

Voclosporin was approved for medical use in the United States in 2021 and Europe in 2022.^[1]^[2] In the United States it costs about 13,400 USD per month.^[3] It is not approved in the United Kingdom as of 2022.^[4] It was previously studied for dry eyes.^[4]

References

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o "Lupkynis- voclosporin capsule". DailyMed. Archived from the original on 30 July 2022. Retrieved 13 September 2021.
^ ^a ^b ^c "Lupkynis EPAR". European Medicines Agency. 19 July 2022. Archived from the original on 22 September 2022. Retrieved 21 September 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ "Lupkynis Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 25 May 2021. Retrieved 1 November 2022.
^ ^a ^b "Voclosporin". SPS - Specialist Pharmacy Service. 22 May 2018. Archived from the original on 3 March 2022. Retrieved 1 November 2022.

[PI2022-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o "Lupkynis- voclosporin capsule". DailyMed. Archived from the original on 30 July 2022. Retrieved 13 September 2021.

[EPAR2022-2] "Lupkynis EPAR". European Medicines Agency. 19 July 2022. Archived from the original on 22 September 2022. Retrieved 21 September 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[3] "Lupkynis Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 25 May 2021. Retrieved 1 November 2022.

[SPS2022-4] "Voclosporin". SPS - Specialist Pharmacy Service. 22 May 2018. Archived from the original on 3 March 2022. Retrieved 1 November 2022.

[1]

[2]

[3]

[4]